Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New Onset Diabetes.

Aim To identify predictors for individualization of antidiabetic therapy in patients with new onset T2DM. Research design and methods 261 drug naive participants in the EDICT study, with new onset diabetes, were randomized in a single-center study to receive: (1) metformin followed by glipizide and then insulin glargine upon failure to achieve HbA1c Results 39 patients started and maintained the treatment goal (HbA1c 2.65 were more likely to achieve glucose control with metformin monotherapy. In patients started on initial Triple Therapy the HbA1c decreased independent of C-Pep120/C-Pep0 ratio. Conclusion The increase in plasma C-peptide concentration above fasting following glucose load predicts the response to antihyperglycemic therapy in patients with new onset diabetes. C-Pep120/C-Pep0 provides a useful tool for individualization of antihyperglycemic therapy in patients with new onset diabetes.